相关实验视频
Updated: May 2, 2026

10:35
Stereotactic Radiosurgery for Gynecologic Cancer
Published on: April 17, 2012
18.7K
利率降低和最佳处方异位剂型模型用于肝脏立体性放射疗法与呼吸运动
Daisuke Kawahara1, Hirokazu Masuda1, Takuya Wada2
1Department of Radiation Oncology, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Hiroshima, Japan.
Journal of applied clinical medical physics
|January 8, 2026
概括
本研究引入了一个虚拟的4DCT框架,以优化肝脏SBRT规划目标体积 (PTV) 利. 它发现,最佳边际可能减少44%,平衡瘤覆盖率和正常组织节省.
科学领域:
- 辐射瘤学 辐射瘤学
- 医学物理 医学物理
- 图像引导疗法是指导图像的疗法.
背景情况:
- 准确的规划目标体积 (PTV) 边缘对于有效的肝脏立体体辐射疗法 (SBRT) 至关重要.
- 呼吸运动显著影响肝脏SBRT中的剂量递送精度.
- 目前用于确定PTV利的方法可能无法完全考虑运动诱导的不确定性.
研究的目的:
- 开发和验证使用虚拟4DCT (v4DCT) 来优化肝脏SBRT中的PTV边缘的框架.
- 引入剂量计覆盖幅度 (DCA) 来量化运动耐受性.
- 为了获得一个最优的边际 (OM),平衡瘤覆盖和正常组织节省.
主要方法:
- 在一个虚拟瘤的全身幻影上利用VMAT计划.
- 使用v4DCT模拟10个阶段的呼吸运动,生成虚拟的4D放射治疗 (v4DRT) 剂量分布.
- 定义DCA为维持瘤总体量 (GTV) 剂量覆盖率的最大呼吸幅度 (D100%或D99%).
- 从异位剂量计划中确定了满足DCA并将正常组织剂量最小化的OM.
主要成果:
- DCA分析显示,GTV覆盖面维持在比传统的10毫米PTV边缘大1.9-2.2倍的运动幅度上.
- 60%的异位剂量计划被认为是最佳的,平衡了GTV覆盖率和正常组织剂量.
- 计算出了5.6毫米的OM,比传统的10毫米PTV利率减少44%.
结论:
- 该v4DCT框架使得在肝脏SBRT中优化PTV边缘.
- 使用60%的异位剂量计划实现了5.6毫米的最佳利率,将常规利率降低了44%.
- 这种方法提供了一种临床上适用的边际降低策略,同时确保了强大的剂量计覆盖率和节省正常组织.
相关概念视频
Radiological Investigation III: Pulmonary Angiogram and PET Scan
722
Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
722
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
97
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97

